Raises $6M to Use Data Science to Help Patients Navigate Specialty Therapies and Clinical Trials Participation
Funding Round Led by IQVIA will Allow the Company to Expand its Offering of Patient Services Across Specialty Pharmacies, and Affordability and Specialty Hubs.
BETHESDA, MD, January 21, 2020 — HelpAround, Inc., the innovator behind the HelpAround Mobile Patient Concierge Platform, announced today its $6M financing round, led by IQVIA (NYSE:IQV), which was joined by existing investors, including Windham Ventures. HelpAround has completed the initial closing of its round and anticipates the final closing to occur in Q1 2020. As part of the agreement, an executive from IQVIA will be joining HelpAround’s board of directors.
HelpAround intends to use the funding to accelerate its growth into the specialty drug market, where approximately 35% of patients discontinue therapy before the first refill.
“Our top priority is to provide patients with a private, secure experience that fits their individual lives,” said Yishai Knobel, co-founder and chief executive officer of HelpAround. “We are excited to have IQVIA lead the round and work with us on the joint mission to improve the lives of millions of patients who are struggling to follow their prescribed therapies.”
“Through our work with HelpAround, we are able to include an adaptive, mobile patient experience as part of our commercialization and clinical trial offerings,” said Gregg Dearhammer, senior vice president of Data Sciences, Safety and Regulatory at IQVIA. “We believe their unique passive data and AIML technology will detect when patients are not adherent to trial protocols, enabling site coordinators and other HCPs to engage on patients’ behalf.”
HelpAround’s platform enables drug manufacturers to adapt therapy on-boarding and trial protocols to the human behind the smartphone. The platform helps patients navigate complex treatments by matching available patient services to the patient’s real-life profile and lifestyle: targeted affordability options, matching to similar peers, on-the-go chat support, and more.
“HelpAround has always been a pioneer in humanizing patient support,” said Chris Bergstrom, Partner & Head of Digital Therapy at BCG Digital Ventures. “The company’s impressive work with renal disease, diabetes, and now in specialty therapies, has the potential of helping millions of patients initiate and adhere to the treatment they need”.
HelpAround was founded by health tech and behavioral targeting veterans. Born out of the notion that there is no such thing as “one size fits all,” the founders believe that just as science is advancing with personalized therapies, patient experience must follow suit. HelpAround aims to help patients and caregivers, overwhelmed by a life-changing condition, to simplify the day-to-day of managing treatment by delivering the information and support resources they need, when they need them, through their smartphones. Visit helparound.co for more information.
IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. Formed through the merger of IMS Health and Quintiles, IQVIA applies human data science — leveraging the analytic rigor and clarity of data science to the ever-expanding scope of human science — to enable companies to reimagine and develop new approaches to clinical development and commercialization, speed innovation and accelerate improvements in healthcare outcomes. Powered by the IQVIA CORE™, IQVIA delivers unique and actionable insights at the intersection of large-scale analytics, transformative technology and extensive domain expertise, as well as execution capabilities. With approximately 65,000 employees, IQVIA conducts operations in more than 100 countries.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.